Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA Monitoring for Postoperative Adjuvant Therapy Decision-Making in Stage III Gastric Cancer: A Prospective, Multicenter, Randomized Controlled Phase III Clinical Trial

NCT06939439 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT06939439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06939439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA Monitoring for Postoperative Adjuvant Therapy Decision-Making in Stage III Gastric Cancer: A Prospective, Multicenter, Randomized Controlled Phase III Clinical Trial
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 1, 2024
Completion date
December 31, 2029
Enrollment
416 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iii